LC-MS/MS method for the quantification of aldose reductase inhibitor - Epalrestat and application to pharmacokinetic study

Journal of Pharmaceutical and Biomedical Analysis

Volumn 74, Issue , 2013, Pages 227-234

  Nirogi, Ramakrishna ^a   Kandikere, Vishwottam ^a   Ajjala, Devender Reddy ^a   Bhyrapuneni, Gopinadh ^a   Muddana, Nageswara Rao ^a  

^a SUVEN LIFE SCIENCES LTD   (India)

Author keywords

Aldose reductase inhibitor; Diabetic neuropathy; Epalrestat; LC MS MS; Motor nerve conduction velocity; Neuropathy pain

Indexed keywords

ACETONITRILE; AMMONIUM ACETATE; EPALRESTAT; FLUINDOSTATIN;

ACCURACY; ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DETERMINATION; DRUG HALF LIFE; DRUG RETENTION; DRUG STABILITY; DRUG STRUCTURE; ELUTION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NONHUMAN; PLASMA CONCENTRATION-TIME CURVE; PRECIPITATION; PRIORITY JOURNAL; RAT; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; VALIDATION PROCESS;

ALDEHYDE REDUCTASE; ANIMALS; CHROMATOGRAPHY, LIQUID; ENZYME INHIBITORS; MALE; RATS; RATS, WISTAR; RHODANINE; TANDEM MASS SPECTROMETRY; THIAZOLIDINES;

EID: 84871894741     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.10.020     Document Type: Article

References (14)

1. Zeigler D. Painful diabetic neuropathy: treatment and future aspects. Diabetes Metab. Res. Rev. 2008, 24:S52-S57.
2. Remirez M.A., Borja N.L. Epalrestat an aldose reductase inhibitor for diabetic neuropathy treatment: conclusion. Pharmacotherapy 2008, 28:646-655.
3. Matsuoaka K., Sakamato N., Akanuma Y., Hotta N., Shichiri M., Toyota T., Oka Y., Kawamori R., Shigeta Y. A long-term effect of epalrestat on motor conduction velocity of diabetic patients: ARI-Diabetes Complications Trial (ADCT). Diabetic Res. Clin. Pract. 2007, 77:S263-S268. ADCT study group.
4. Chie O., Hirotala W., Kosuke A., Tomoaki S., Akio K., Fuki I., Tomoaki Y., Yoshio F., Takahisa H., Yasushi T., Ryuzo K. Aldose reductase inhibitor, epalrestat, reduces lipid hydroperoxides in type 2 diabetes. Endocr. J. 2009, 56:149-156.
5. Chylack L.T., Kinoshita J.H. A biochemical evaluation of a cataract induced in a high-glucose medium. Invest. Ophthamol. 1969, 8:401-412.
6. Kinoshita J.H., Kador P., Catiles M. Aldose reductase in diabetic cataracts. JAMA 1981, 246:257-261.
7. Oates P.J., Mylari B.L. Aldose reductase inhibitors: therapeutic implications for diabetic complications. Expert Opin. Investig. Drugs 1999, 8:2095-2119.
8. Ono Pharmaceutical Co, Ltd. Kinedak (epalrestat) Package Insert, Chuo-ku, Osaka, Japan, 2005.
9. Steele J.W., Faulds D., Goa K.L. Epalrestat a review of its pharmacology, and therapeutic potential in late-onset complications in diabetes mellitus. Drugs Aging 1993, 3:532-555.
10. Sawada M., Terashima H., Okegava T., Kawasaki A. Current concepts in aldose reductase inhibitors. Proceedings of the Japan US Aldose Reductase Workshop 1990, 111-118. Elsevier Science Publishers BV, Amsterdam.
11. Nirogi R., Kandikere V., et al. Quantification of cinacalcet by LC-MS/MS using liquid-liquid extraction from 50μL of plasma. J. Pharm. Biomed. Anal. 2011, 56:373-381.
12. Ding X., Morrison G., et al. A solid phase extraction-liquid chromatographic-tandem mass spectrometry method for determination of concentrations of GDC-0941, a small molecule class I phosphatidylinositide 3-kinase inhibitor, to support clinical development. J. Pharm. Biomed. Anal. 2012, 61:1-7.
13. Pshenichnyuk A.S., Modelli A. Complex fragmentation pathway of rhodanine and rhodanine 3-acetic acid upon capture of low-energy electrons. Int. J. Mass Spectrom. 2010, 294:93-102.
14. US Department of Health and Human Services, FDA, CDER, CVM, Guidance for Industry - Bioanalytical Method Validation 2001, Center for Drug Evaluation and Research (CDER), Rockville.